Biogen (BIIB) is a Biotechnology company. Biogen sells multiple sclerosis drugs (Tecfidera, Vumerity, Tysabri, interferons) and a growth book in SMA (Spinraza), Friedreich ataxia (Skyclarys), postpartum depression (Zurzuvae), and Alzheimer disease through the Eisai Leqembi collaboration. The May 2026 Apellis deal added Syfovre and Empaveli. It was founded in 1978, is headquartered in Cambridge, Massachusetts and employs about 7,500 people.

How does Biogen make money?

As of 2026-Q2, Biogen's revenue breaks down across MS Product Revenues (41%), TYSABRI product (19%), SPINRAZA (17%), Fumarate (12%). See the revenue-by-segment chart for the full mix.

How has Biogen's revenue and profitability trended?

Track Biogen's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 26, 2026.

Who are Biogen's main competitors?

Sterling groups Biogen in the Healthcare sector, alongside Gilead Sciences (GILD), Incyte (INCY) and Vertex Pharmaceuticals (VRTX).

If I'm investing in Biogen, what similar companies should I consider?

If you are researching Biogen, also look at Gilead Sciences (GILD), Incyte (INCY) and Vertex Pharmaceuticals (VRTX). You can compare all of them side by side or browse the full Healthcare sector on Sterling.